DM0000: The mark consists of a stylized version of the literal element "RETHINK ADHD SYMPTOM CONTROL" in a single, horizontal line.
GS0051: Pharmaceutical preparations for therapeutic use in humans, namely, for the treatment and prevention of central nervous system and peripheral nervous system diseases and disorders, psychiatric and neurological diseases and disorders
PM0001: RETHINK ATTENTION DEFICIT HYPERACTIVITY DISORDER SYMPTOM CONTROL
CC0000: Color is not claimed as a feature of the mark.
Case File Event Statements
3/8/2022 - 3 years ago
16 - REGISTERED-PRINCIPAL REGISTERType:R.PR
2/3/2022 - 3 years ago
15 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILEDType:SUNA
2/2/2022 - 3 years ago
14 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTEDType:CNPR
1/31/2022 - 3 years ago
13 - STATEMENT OF USE PROCESSING COMPLETEType:SUPC
1/13/2022 - 3 years ago
12 - USE AMENDMENT FILEDType:IUAF
1/28/2022 - 3 years ago
11 - CASE ASSIGNED TO INTENT TO USE PARALEGALType:AITU
1/13/2022 - 3 years ago
10 - TEAS STATEMENT OF USE RECEIVEDType:EISU
7/13/2021 - 3 years ago
9 - NOA E-MAILED - SOU REQUIRED FROM APPLICANTType:NOAM
5/18/2021 - 4 years ago
8 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILEDType:NPUB
5/18/2021 - 4 years ago
7 - PUBLISHED FOR OPPOSITIONType:PUBO
4/28/2021 - 4 years ago
6 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILEDType:NONP
4/13/2021 - 4 years ago
5 - WITHDRAWN FROM PUB - OG REVIEW QUERYType:PBCR
3/30/2021 - 4 years ago
4 - APPROVED FOR PUB - PRINCIPAL REGISTERType:CNSA
3/30/2021 - 4 years ago
3 - ASSIGNED TO EXAMINERType:DOCK
12/22/2020 - 4 years ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAMType:NWOS